Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jarno Hoekman"'
Autor:
Rick A. Vreman, Lourens T. Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E. van der Elst, Hubert GM Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel-Teeuwisse
Publikováno v:
International Journal of Health Policy and Management, Vol 11, Iss 5, Pp 642-650 (2022)
BackgroundThe European Medicines Agency (EMA) aims to resolve uncertainties associated with conditionally approved drugs by imposing post-approval studies. Results from these studies may be relevant for health technology assessment (HTA) organization
Externí odkaz:
https://doaj.org/article/b08a5601b3234a34901de533ff590f12
Autor:
Lourens T. Bloem, Rick A. Vreman, Niels W. L. Peeters, Jarno Hoekman, Menno E. van derElst, Hubert G. M. Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel‐Teeuwisse
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1566-1577 (2021)
Abstract We aimed to determine whether uncertainties identified by the European Medicines Agency (EMA) were associated with negative relative effectiveness assessments (REAs) and negative overall reimbursement recommendations by national health techn
Externí odkaz:
https://doaj.org/article/a2e8481c77804dc8b050c8e96f840417
Publikováno v:
Quantitative Science Studies, Vol 1, Iss 3, Pp 1203-1222 (2020)
AbstractScientific breakthroughs are commonly understood as discoveries that transform the knowledge frontier and have a major impact on science, technology, and society. Prior literature studying breakthroughs generally treats them as a homogeneous
Externí odkaz:
https://doaj.org/article/fbdedb9552be4aee8aff5ae4f18ad796
Autor:
Renske M.T. ten Ham, Jarno Hoekman, Anke M. Hövels, Andre W. Broekmans, Hubert G.M. Leufkens, Olaf H. Klungel
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 11, Iss , Pp 121-130 (2018)
Advanced therapy medicinal products (ATMPs) hold promise as treatments for previously untreatable and high-burden diseases. Expectations are high and active company pipelines are observed, yet only 10 market authorizations were approved in Europe. Ou
Externí odkaz:
https://doaj.org/article/d1e10b2078114479a61d2de16d64634b
Autor:
Tom G. Jacobs, H. Hilda Ampadu, Jarno Hoekman, Alexander N. O. Dodoo, Aukje K. Mantel-Teeuwisse
Publikováno v:
BMC Public Health, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Under-reporting of adverse drug reactions (ADRs) is a major challenge for pharmacovigilance in Africa. This study sets out to assess the level of awareness of Ghanaian patients about ADRs and ADR-reporting and explores how differe
Externí odkaz:
https://doaj.org/article/1cc07c4dadb14ca48a5525cb166265bd
Autor:
H. Hilda Ampadu, Jarno Hoekman, Daniel Arhinful, Marilyn Amoama-Dapaah, Hubert G. M. Leufkens, Alex N. O. Dodoo
Publikováno v:
Globalization and Health, Vol 14, Iss 1, Pp 1-17 (2018)
Abstract Background National pharmacovigilance centres (national centres) are gradually gaining visibility as part of the healthcare delivery system in Africa. As does happen in high-income countries, it is assumed that national centres can play a ce
Externí odkaz:
https://doaj.org/article/11ef0c7d77fb41f1b484515b7f14011d
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108722 (2014)
There is discussion whether medicines can be authorized on the market based on evidence from surrogate endpoints. We assessed opinions of different stakeholders on this topic.We conducted an online questionnaire that targeted various stakeholder grou
Externí odkaz:
https://doaj.org/article/dac91dee390d420ea9acbc1932019aae
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e45984 (2012)
Pharmaceutical trials are mainly initiated by sponsors and investigators in the United States, Western Europe and Japan. However, more and more patients are enrolled in Central and Eastern Europe, Latin America and Asia. The involvement of patients i
Externí odkaz:
https://doaj.org/article/6f7645e248574e029bbbed86557e3890
Publikováno v:
Research Evaluation.
While there is a prolific debate on evaluating the societal impact of academic research, so far little attention has been paid to assessing the design and implementation of suitable organizational strategies. This article argues that evaluation metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e5635f01a01fab207a3c46aad68070d
https://doi.org/10.1093/reseval/rvac045
https://doi.org/10.1093/reseval/rvac045
Autor:
Lotte A. Minnema, Toine C. G. Egberts, Hubert G. M. Leufkens, Helga Gardarsdottir, Jarno Hoekman, Thijs J. Giezen
Publikováno v:
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 110(1), 123. Nature Publishing Group
Clinical Pharmacology and Therapeutics, 110(1), 123. Nature Publishing Group
The summary of product characteristics (SmPC) is an important information source that includes the adverse drug reactions (ADRs) associated with the drug. Drugs with the same mechanism of action are expected to have a similar ADR profile and thus a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd40a01c1bd774decf571e837e2a6c80
https://pubmed.ncbi.nlm.nih.gov/33278830
https://pubmed.ncbi.nlm.nih.gov/33278830